HK Stock Market Move | WUXI BIO(02269) rises over 6% again, net profit far exceeds expectations in the second half of last year after adjustment, gross profit margin significantly increases.

WUXI BIO (02269) surged more than 6%, with a 5.6% increase as of the time of writing, reaching 43.72 Hong Kong dollars, with a turnover of 8.78 billion Hong Kong dollars. On the news front, WUXI BIO recently released a performance forecast, expecting a revenue growth of about 16.7% to 21.79 billion yuan in 2025; net profit attributable to shareholders is expected to increase by 46.3% to 4.908 billion yuan year-on-year; adjusted profit is expected to increase by 22.0% to 6.586 billion yuan year-on-year; gross profit margin is expected to increase to 46.0%, an increase of about 5 percentage points year-on-year. A research report released by Lyon stated that WUXI BIO is pleasantly surprised by its performance in the second half of 2025, expecting a 17% year-on-year increase in revenue, which is in line with expectations; adjusted net profit is expected to increase by 31% to 3.7 billion yuan year-on-year, far surpassing market expectations; gross profit margin is expected to increase by 6.2 percentage points year-on-year to 48.8%, which is the core positive surprise in this earnings surprise, and is the main driver of performance exceeding expectations. The bank stated that WUXI BIO remains one of the preferred stocks in the Chinese CRO and CDMO industry.